Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
– Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand... Read more.
Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™
Combined market up 46%, led by 64% growth in cloud services Managed services up 21%, as companies seek cost savings to fund AI LONDON–(BUSINESS WIRE)–$III... Read more.
Maureen Mahr von Staszewski Joins Heitman European Leadership Team
Heitman expands European platform with addition of experienced leader LONDON–(BUSINESS WIRE)–Heitman LLC (“Heitman”), a global real estate investment... Read more.
Marti and Tensor Partner to Deploy Autonomous Vehicles in Türkiye
ISTANBUL–(BUSINESS WIRE)–Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye’s leading mobility super app, and... Read more.
PropertyStream and Offr Launch TRANSACT as UK Homebuying Enters the Digital Era
The new partnership combines award-winning estate agency websites with end-to-end transaction technology to help real estate agents prepare for the future of digital... Read more.
Sofinnova Partners Appoints David Evans as Partner
Sofinnova strengthens its growth strategy with a high-caliber London-based Partner: Physician-scientist combining frontline clinical experience, health financing... Read more.
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
SURPASS-IPF is the first industry-sponsored head-to-head Phase 3 trial in IPF and will evaluate the superiority of deupirfenidone 825 mg TID vs. pirfenidone 801... Read more.
Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
SURPASS-IPF is the first industry-sponsored head-to-head Phase 3 trial in IPF and will evaluate the superiority of deupirfenidone 825 mg TID vs. pirfenidone 801... Read more.
MileOne Autogroup Ranked Highest in New 2026 Service Scheduling Effectiveness Omnichannel Study
First-ever omnichannel study measured how effectively each group’s dealerships helped customers schedule service by either phone or dealer website. Competitive... Read more.
Churchill Asset Management and Seviora Close Approximately $400 Million Collateralized Fund Obligation Combining U.S. and Asian Private Capital Strategies
Providing institutional investors with diversified access to private capital opportunities across geographies and strategies NEW YORK & SINGAPORE–(BUSINESS... Read more.